Abstract
Cognitive dysfunction is a core feature of psychosis-spectrum illnesses, and the characterization of related genetic mechanisms may provide insights regarding the disease pathophysiology. Substantial efforts have been made to determine the genetic component of cognitive symptoms, without clear success. Illness-related moderators and environmental factors such as medications hinder the detection of genomic association with cognition. Polypharmacy is common in psychotic disorders, and the cumulative effects of medication regimens can confound gene-cognition associations. A review of the relative contributions of important pharmacological and genetic relationships identifies that the effects of medications on cognition in psychotic disorders may be at least, if not more, impactful than individual genes, thus underscoring the importance of accounting for medication exposure in gene-cognition association studies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 791-806 |
| Number of pages | 16 |
| Journal | Pharmacogenomics |
| Volume | 23 |
| Issue number | 14 |
| DOIs | |
| State | Published - Sep 1 2022 |
Keywords
- anticholinergics
- antidopaminergics
- BDNF
- cognition
- COMT
- genomic associations
- medication exposure
- psychotic disorders
PubMed: MeSH publication types
- Journal Article
- Review